Clinical Trial Update: ZD6474(Vandetanib) + Alimta Combo Study [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating Vandetanib (ZD6474) in combination with Alimta (pemetrexed) for non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Vandetanib (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Carcinoma, Non-Small Cell Lung | Phase 1 | Status: COMPLETED